Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - CTI BIOPHARMA CORPFinancial_Report.xls
10-Q - FORM 10-Q - CTI BIOPHARMA CORPd10q.htm
EX-32 - CERTIFICATION OF CEO AND CFO PURSUANT TO SECTION 906 - CTI BIOPHARMA CORPdex32.htm
EX-10.4 - RESTRICTED STOCK AWARD AGREEMENT - CTI BIOPHARMA CORPdex104.htm
EX-31.2 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 - CTI BIOPHARMA CORPdex312.htm
EX-31.1 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 - CTI BIOPHARMA CORPdex311.htm

Exhibit No. 15

July 28, 2011

Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

Commissioners:

We are aware that our report dated July 28, 2011 on our review of interim financial information of Cell Therapeutics, Inc. for the six month period ended June 30, 2011 included in the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2011 is incorporated by reference in the Registration Statements of Cell Therapeutics, Inc. on Forms S-3 (File Nos. 333-130411, 333-131533, 333-130004, 333-36038, 333-41300, 333-67906, 333-36603, 333-38431, 333-108926, 333-112681, 333-138170, 333-134126, 333-143452, 333-149980, 333-149981, 333-149982, 333-152171, 333-160969, 333-158272, 333-157376, 333-153358, 333-163479, 333-161442, 333-93835, 333-33872, 333-33268, and 333-39385) and on Form S-8 (File No. 333-65200, 333-58957, 333-35919, 333-97015, 333-106568, 333-106571, 333-112791, 333-118016, 333-146624, 333-152168, 333-158260, 333-162955, and 333-170044).

Yours very truly,

/s/ Marcum LLP